Primary |
Product Used For Unknown Indication |
63.7% |
Pain |
18.2% |
Back Pain |
3.1% |
Cancer Pain |
3.1% |
Depression |
1.3% |
Hypertension |
1.1% |
Pain Management |
0.9% |
Insomnia |
0.9% |
Osteoarthritis |
0.9% |
Arthralgia |
0.8% |
Breakthrough Pain |
0.8% |
Analgesic Therapy |
0.6% |
Breast Cancer Metastatic |
0.6% |
Hepatic Cancer |
0.6% |
Intervertebral Disc Protrusion |
0.6% |
Neuralgia |
0.6% |
Plasma Cell Myeloma |
0.6% |
Sciatica |
0.5% |
Spinal Pain |
0.5% |
Anxiety |
0.5% |
|
Wrong Technique In Drug Usage Process |
39.5% |
Off Label Use |
15.0% |
Product Quality Issue |
10.4% |
Drug Prescribing Error |
7.9% |
Inappropriate Schedule Of Drug Administration |
5.6% |
Vomiting |
4.8% |
Somnolence |
4.6% |
Overdose |
1.5% |
Medication Error |
1.2% |
Pain |
1.2% |
Toxicity To Various Agents |
1.0% |
Withdrawal Syndrome |
1.0% |
Incorrect Drug Administration Duration |
0.8% |
Intentional Drug Misuse |
0.8% |
Intestinal Obstruction |
0.8% |
Product Adhesion Issue |
0.8% |
Treatment Noncompliance |
0.8% |
Urinary Retention |
0.8% |
Disease Progression |
0.6% |
Drug Administration Error |
0.6% |
|
Secondary |
Product Used For Unknown Indication |
41.2% |
Pain |
19.9% |
Back Pain |
7.8% |
Cancer Pain |
5.8% |
Intervertebral Disc Protrusion |
5.2% |
Hypertension |
2.5% |
Electrolyte Substitution Therapy |
1.7% |
Fibromyalgia |
1.6% |
Arthralgia |
1.5% |
Drug Use For Unknown Indication |
1.5% |
Sciatica |
1.4% |
Abdominal Pain |
1.2% |
Osteoporosis |
1.2% |
Thrombosis Prophylaxis |
1.2% |
Hypothyroidism |
1.1% |
Bone Pain |
1.0% |
Breast Cancer |
1.0% |
Osteoarthritis |
1.0% |
Squamous Cell Carcinoma |
0.9% |
Stupor |
0.9% |
|
Wrong Technique In Drug Usage Process |
39.3% |
Vomiting |
8.9% |
Off Label Use |
6.1% |
Somnolence |
5.6% |
Withdrawal Syndrome |
5.6% |
Inappropriate Schedule Of Drug Administration |
5.1% |
Drug Prescribing Error |
3.7% |
Product Quality Issue |
3.3% |
Treatment Noncompliance |
2.8% |
Pain |
2.3% |
Death |
1.9% |
Hepatitis |
1.9% |
Hepatitis Acute |
1.9% |
Malaise |
1.9% |
Monocytopenia |
1.9% |
Urinary Retention |
1.9% |
Weight Increased |
1.9% |
Overdose |
1.4% |
Psoriasis |
1.4% |
Renal Failure |
1.4% |
|
Concomitant |
Product Used For Unknown Indication |
34.0% |
Pain |
11.4% |
Plasma Cell Myeloma |
7.1% |
Hypertension |
7.0% |
Prophylaxis |
5.8% |
Tumour Pain |
3.8% |
Depression |
3.7% |
Breast Cancer Metastatic |
3.1% |
Bone Pain |
2.7% |
Metastases To Bone |
2.4% |
Back Pain |
2.3% |
Drug Use For Unknown Indication |
2.3% |
Thrombosis Prophylaxis |
2.2% |
Osteoporosis |
2.0% |
Atrial Fibrillation |
1.8% |
Prostate Cancer |
1.8% |
Constipation |
1.7% |
Non-small Cell Lung Cancer |
1.7% |
Rheumatoid Arthritis |
1.7% |
Anticoagulant Therapy |
1.6% |
|
Vomiting |
15.0% |
Thrombocytopenia |
12.4% |
Weight Decreased |
8.8% |
Osteonecrosis Of Jaw |
6.2% |
Renal Failure Acute |
6.2% |
Septic Shock |
6.2% |
Off Label Use |
4.4% |
Pyrexia |
4.4% |
Death |
3.5% |
General Physical Health Deterioration |
3.5% |
Lung Disorder |
3.5% |
Rash |
3.5% |
Rhabdomyolysis |
3.5% |
Disease Progression |
2.7% |
Febrile Bone Marrow Aplasia |
2.7% |
Gastrointestinal Haemorrhage |
2.7% |
Malaise |
2.7% |
Neutropenia |
2.7% |
Osteonecrosis |
2.7% |
Pain |
2.7% |
|
Interacting |
Product Used For Unknown Indication |
56.0% |
Pain |
12.0% |
Ascites |
8.0% |
Plasma Cell Myeloma |
8.0% |
Arterial Stenosis |
4.0% |
Chronic Hepatitis |
4.0% |
Hyperlipidaemia |
4.0% |
Lymphoma |
4.0% |
|
Drug Interaction |
40.0% |
Cardio-respiratory Arrest |
20.0% |
Renal Impairment |
20.0% |
Vomiting Projectile |
20.0% |
|